Jan. 3, 2013
/PRNewswire/ -- Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced that company founder
, Ph.D., will present at the 31
Annual J.P. Morgan Healthcare Conference in
. Dr. Newton's presentation will take place on
Tuesday, January 8
3 PM PST
in Elizabethan C/D Room 120 of the Westin St. Francis Hotel.
About Esperion TherapeuticsEsperion Therapeutics, Inc. discovers and develops novel therapies for the treatment of cardiometabolic diseases. The company's lead product candidate, ETC-1002, is an AMP kinase activator and ATP citrate lyase inhibitor that is being evaluated in multiple Phase 2 clinical trials for the treatment of hypercholesterolemia and other cardiometabolic risk factors. Esperion intends to commercialize innovative, first-in-class therapies focused on enhancing lipid regulation, addressing statin intolerance and improving overall cardiometabolic health. For more information, please visit
SOURCE Esperion Therapeutics, Inc.